Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables: 2010-2025

Historic Receivables for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $120.4 million.

  • Ironwood Pharmaceuticals' Receivables rose 58.00% to $120.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $328.3 million, marking a year-over-year decrease of 2.13%. This contributed to the annual value of $81.9 million for FY2024, which is 36.57% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Receivables of $120.4 million as of Q3 2025, which was up 39.68% from $86.2 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Receivables ranged from a high of $138.0 million in Q4 2021 and a low of $39.8 million during Q1 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Receivables averaged around $93.0 million, with its median value being $86.2 million (2025).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Receivables plummeted by 51.17% in 2024 and then surged by 58.00% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Receivables (Quarterly) stood at $138.0 million in 2021, then declined by 5.80% to $130.0 million in 2022, then fell by 0.68% to $129.1 million in 2023, then slumped by 36.57% to $81.9 million in 2024, then soared by 58.00% to $120.4 million in 2025.
  • Its last three reported values are $120.4 million in Q3 2025, $86.2 million for Q2 2025, and $39.8 million during Q1 2025.